Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer

Compensatory activation of the signal transduction pathways is one of the major obstacles for the targeted therapy of non‐small cell lung cancer (NSCLC). Herein, we present the therapeutic strategy of combined targeted therapy against the MEK and phosphoinositide‐3 kinase (PI3K) pathways for acquire...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Sci
Egile Nagusiak: Sato, Hiroki, Yamamoto, Hiromasa, Sakaguchi, Masakiyo, Shien, Kazuhiko, Tomida, Shuta, Shien, Tadahiko, Ikeda, Hirokuni, Hatono, Minami, Torigoe, Hidejiro, Namba, Kei, Yoshioka, Takahiro, Kurihara, Eisuke, Ogoshi, Yusuke, Takahashi, Yuta, Soh, Junichi, Toyooka, Shinichi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2018
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6172047/
https://ncbi.nlm.nih.gov/pubmed/30098066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13763
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak